The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome

Seminars in Liver Disease

Volumn 36, Issue 4, 2016, Pages 312-316

  Quigley, Eamonn M M ^a   Abu Shanab, Ahmed ^b   Murphy, Eileen F ^c   Stanton, Catherine ^d   Monsour, Howard P ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c ALIMENTARY HEALTH LTD   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

alcohol; choline; gut permeability; microbiome; microbiota; nonalcoholic fatty liver disease; nonalcoholic steatosis

Indexed keywords

ALCOHOL; BILE ACID; CHEMOKINE; CHOLINE; CYTOKINE; TOLL LIKE RECEPTOR;

ALCOHOL PRODUCTION; ARTICLE; BACTERIAL OVERGROWTH; BILE ACID METABOLISM; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; COMPLICATION; IMMUNOLOGY; INTESTINE; LIVER; METABOLISM; MICROBIOLOGY; OBESITY; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; LIVER; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 85006880839     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0036-1593880     Document Type: Article

References (82)

1. Turnbaugh P. J., Gordon J. I. The core gut microbiome, energy balance and obesity. J Physiol: 2009; 587 Pt 17 4153 4158
2. Marchesi J. R., Adams D. H., Fava F., et al. The gut microbiota and host health: a new clinical frontier. Gut: 2016; 65 2 330 339
3. Jones B. V., Begley M., Hill C., Gahan C. G., Marchesi J. R. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A: 2008; 105 36 13580 13585
4. Carmody R. N., Turnbaugh P. J. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest: 2014; 124 10 4173 4181
5. Quigley E. M., Stanton C., Murphy E. F. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol: 2013; 58 5 1020 1027
6. Gérard P. Gut microbiota and obesity. Cell Mol Life Sci: 2016; 73 1 147 162
7. Mazidi M., Rezaie P., Kengne A. P., Mobarhan M. G., Ferns G. A. Gut microbiome and metabolic syndrome. Diabetes Metab Syndr: 2016; 10 2 01 S150 S157
8. Leung C., Rivera L., Furness J. B., Angus P. W. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol: 2016; 13 7 412 425
9. Ley R. E., Bäckhed F., Turnbaugh P., Lozupone C. A., Knight R. D., Gordon J. I. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A: 2005; 102 31 11070 11075
10. Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R., Gordon J. I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature: 2006; 444 7122 1027 1031
11. Ridaura V. K., Faith J. J., Rey F. E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science: 2013; 341 6150 1241214
12. Galley J. D., Bailey M., Kamp Dush C., Schoppe-Sullivan S., Christian L. M. Maternal obesity is associated with alterations in the gut microbiome in toddlers. PLoS One: 2014; 9 11 e113026
13. Parks B. W., Nam E., Org E., et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab: 2013; 17 1 141 152
14. Dugas L. R., Fuller M., Gilbert J., Layden B. T. The obese gut microbiome across the epidemiologic transition. Emerg Themes Epidemiol: 2016; 13 2
15. Woting A., Blaut M. The intestinal microbiota in metabolic disease. Nutrients: 2016; 8 4 202
16. Houghton D., Stewart C. J., Day C. P., Trenell M. Gut microbiota and lifestyle interventions in NAFLD. Int J Mol Sci: 2016; 17 4 447
17. Yatsunenko T., Rey F. E., Manary M. J., et al. Human gut microbiome viewed across age and geography. Nature: 2012; 486 7402 222 227
18. Moschen A. R., Wieser V., Tilg H. Dietary factors: major regulators of the gut's microbiota. Gut Liver: 2012; 6 4 411 416
19. Clarke S. F., Murphy E. F., Nilaweera K., et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes: 2012; 3 3 186 202
20. Claesson M. J., Jeffery I. B., Conde S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature: 2012; 488 7410 178 184
21. Clarke S. F., Murphy E. F., O'Sullivan O., et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut: 2014; 63 12 1913 1920
22. Hacquard S., Garrido-Oter R., González A., et al. Microbiota and host nutrition across plant and animal kingdoms. Cell Host Microbe: 2015; 17 5 603 616
23. Doré J., Blottière H. The influence of diet on the gut microbiota and its consequences for health. Curr Opin Biotechnol: 2015; 32 195 199
24. Hildebrandt M. A., Hoffmann C., Sherrill-Mix S. A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology: 2009; 137 5 1716 24.e1, 2
25. Murphy E. F., Cotter P. D., Healy S., et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut: 2010; 59 12 1635 1642
26. Machado M. V., Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol: 2012; 11 4 440 449
27. Sayin S. I., Wahlström A., Felin J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab: 2013; 17 2 225 235
28. Li F., Jiang C., Krausz K. W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun: 2013; 4 2384
29. Cox L. M., Blaser M. J. Pathways in microbe-induced obesity. Cell Metab: 2013; 17 6 883 894
30. Cryan J. F., Dinan T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci: 2012; 13 10 701 712
31. Mayer E. A., Tillisch K., Gupta A. Gut/brain axis and the microbiota. J Clin Invest: 2015; 125 3 926 938
32. Perry R. J., Peng L., Barry N. A., et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature: 2016; 534 7606 213 217
33. Cani P. D., Amar J., Iglesias M. A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes: 2007; 56 7 1761 1772
34. Erridge C., Attina T., Spickett C. M., Webb D. J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr: 2007; 86 5 1286 1292
35. Amar J., Burcelin R., Ruidavets J. B., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr: 2008; 87 5 1219 1223
36. Penas-Steinhardt A., Barcos L. S., Belforte F. S., et al. Functional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweight. PLoS One: 2012; 7 12 e50992
37. Kim K-A, Gu W., Lee I-A, Joh E-H, Kim D-H. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signalling pathway. PLoS One: 2012; 7 e47713
38. Vijay-Kumar M., Aitken J. D., Carvalho F. A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science: 2010; 328 5975 228 231
39. Turnbaugh P. J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature: 2009; 457 7228 480 484
40. Greenblum S., Turnbaugh P. J., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A: 2012; 109 2 594 599
41. Karlsson F. H., Tremaroli V., Nookaew I., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature: 2013; 498 7452 99 103
42. Zupancic M. L., Cantarel B. L., Liu Z., et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS One: 2012; 7 8 e43052
43. Walters W. A., Xu Z., Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett: 2014; 588 22 4223 4233
44. Quigley E. M. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci: 1996; 41 3 557 561
45. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol: 2015; 7 3 425 442
46. Abu-Shanab A., Quigley E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol: 2010; 7 12 691 701
47. Quigley E. M., Monsour H. P. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis: 2015; 35 3 262 269
48. Wigg A. J., Roberts-Thomson I. C., Dymock R. B., McCarthy P. J., Grose R. H., Cummins A. G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut: 2001; 48 2 206 211
49. Shanab A. A., Scully P., Crosbie O., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci: 2011; 56 5 1524 1534
50. Bajaj J. S., Hylemon P. B., Ridlon J. M., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol: 2012; 303 6 G675 G685
51. Qin N., Yang F., Li A., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature: 2014; 513 7516 59 64
52. Bajaj J. S., Heuman D. M., Hylemon P. B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol: 2014; 60 5 940 947
53. Raman M., Ahmed I., Gillevet P. M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: 2013; 11 7 868 75.e1, 3
54. Mouzaki M., Comelli E. M., Arendt B. M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology: 2013; 58 1 120 127
55. Zhu L., Baker S. S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology: 2013; 57 2 601 609
56. Wong V. W-S, Tse C-H, Lam T. T-Y., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis - a longitudinal study. PLoS One: 2013; 8 4 e62885
57. Jiang W., Wu N., Wang X., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep: 2015; 5 8096
58. Quigley E. M. Leaky gut-concept or clinical entity? Curr Opin Gastroenterol: 2016; 32 2 74 79
59. Spencer M. D., Hamp T. J., Reid R. W., Fischer L. M., Zeisel S. H., Fodor A. A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology: 2011; 140 3 976 986
60. Engstler A. J., Aumiller T., Degen C., et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut: 2016; 65 9 1564 1571
61. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature: 2012; 482 7384 179 185
62. Sawada K., Ohtake T., Hasebe T., et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice. Hepatol Res: 2014; 44 8 920 934
63. Wagnerberger S., Spruss A., Kanuri G., et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr: 2012; 107 12 1727 1738
64. Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol: 2014; 20 23 7381 7391
65. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol: 2012; 590 3 447 458
66. Jiang C., Xie C., Li F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest: 2015; 125 1 386 402
67. Schnabl B., Brenner D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology: 2014; 146 6 1513 1524
68. Chassaing B., Etienne-Mesmin L., Gewirtz A. T. Microbiota-liver axis in hepatic disease. Hepatology: 2014; 59 1 328 339
69. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol: 2008; 48 6 983 992
70. Vrieze A., Out C., Fuentes S., et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol: 2014; 60 4 824 831
71. Gangarapu V., Ince A. T., Baysal B., et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol: 2015; 27 7 840 845
72. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology: 2012; 143 4 913 6.e7
73. Chambers E. S., Viardot A., Psichas A., et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut: 2015; 64 11 1744 1754
74. Polyzos S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., Kountouras J. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study. Arq Gastroenterol: 2014; 51 3 261 268
75. Mouzaki M., Bandsma R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease. Curr Drug Targets: 2015; 16 12 1324 1331
76. Lirussi F., Mastropasqua E., Orando S., Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev: 2007; 1 CD005165
77. Tarantino G., Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol: 2015; 10 5 889 902
78. Sáez-Lara M. J., Robles-Sanchez C., Ruiz-Ojeda F. J., Plaza-Diaz J., Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci: 2016; 17 6 928
79. Ferolla S. M., Armiliato G. N., Couto C. A., Ferrari T. C. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients: 2014; 6 12 5583 5599
80. Llorente C., Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol: 2015; 1 3 275 284
81. Yuan L., Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol: 2015; 7 28 2811 2818
82. Wan X., Xu C., Yu C., Li Y. Role of NLRP3 inflammasome in the progression of NAFLD to NASH. Can J Gastroenterol Hepatol: 2016; 2016 6489012